Pharsight Corporation And FDA Collaborate On Critical Path Initiative To Implement State-Of-The-Art Infrastructure For Model-Based Drug Development

MOUNTAIN VIEW, Calif., June 7 /PRNewswire-FirstCall/ -- Pharsight Corporation (OTC Bulletin Board: PHST - News), a leading provider of software and strategic services designed to optimize clinical drug development, today announced that it has entered into a Cooperative Research and Development Agreement (CRADA) with the Food and Drug Administration's (FDA) Center for Drug Evaluation and Research (CDER).